TP53 and acute myeloid leukemia: Despite the efficacy of CPX-351 shown in t-AML and high-risk groups [55], several data overall support the hypothesis that resistance to liposomal daunorubicin and cytarabine chemotherapy is common in AML patients with TP53 mutations [56,57].